Clinical Trials for Cancer Treatment

Study Title:

A011801 - THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB

What is the purpose of the study? (in Layman's terms, please describe the study)

This study is being done to answer the following question:
Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your breast cancer. The usual approach is defined as care most people get for breast cancer.

Upstate Institutional Review Board (IRB) Number:

1720504

Study/Protocol ID:

A011801

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

What is involved if I participate?

How long is the study?
10 years
Is transportation provided or reimbursed?
No
Is parking provided or reimbursed?
No
What tests and procedures are involved?
If you join the study, you will have more exams, tests, and procedures to closely monitor your safety and health.